Table 2

Frequency distribution of Chromosome Aberrations (CA) in 500 bone marrow cells examined (100 cells from each individuals).



Mitotic Index
 Chromosome Aberration
 Micronucleated Erythrocyte
 Sperm Head Anomaly
Intervals (hr)
 Drug potency
 Series
 % ± SE
 % of Increased MI
 % of Major CA
 % of Other CA
 Total CA ± SE
 Prot.
 % of MN in NCE
 % of MN in PCE
 P/N
 % of Total MN in NCE & PCE
 % of Prot,
 % of SHA ± SE
 % of prot.
6
 30
 T3
 1.72 ± 0.18
3.2
 6
 9.2 ± 0.82
0.15
 1.07
 0.12
 0.25 ± 0.04
1.62 ± 0.20


C3
 1.84 ± 0.20
 -0.12
 3.8
 7.4
 11.2 ± 0.96
 2.0
 0.23
 0.73
 0.32
 0.35 ± 0.02
 0.10a
 1.68 ± 0.25
 0.06

200
 T4
 1.98 ± 0.23
3.4
 5.2
 8.6 ± 1.20
0.2
 0.67
 0.13
 0.25 ± 0.04
1.48 ± 0.19


C4
 1.6 ± 0.18
 0.38
 5
 6.6
 11.6 ± 1.44
 3.0
 0.23
 0.51
 0.30
 0.29 ± 0.03
 0.04a
 1.56 ± 0.18
 0.08
12
 30
 T3
 1.84 ± 0.14
6
 6.8
 12.8 ± 0.82
0.2
 0.58
 0.25
 0.27 ± 0.04
1.64 ± 0.18


C3
 1,36 ± 0,17
 0.48
 7.6
 9.8
 17.4 ± 1.44
 4.6a
 0.43
 0.64
 0.45
 0.49 ± 0.05
 0.22a
 2.12 ± 0.26
 0.48

200
 T4
 2.08 ± 0.14
4.8
 4.8
 9.6 ± 1.03
0.17
 0.41
 0.23
 0.21 ± 0.02
1.32 ± 0.16


C4
 1.38 ± 0.19
 0.7a
 6.8
 9.8
 16.6 ± 1.60
 7.0a
 0.4
 0.57
 0.45
 0.47 ± 0.06
 0.26a
 2.04 ± 0.23
 0.72a
24
 30
 t3
 1.7 ± 0.33
8.2
 9.4
 17.6 ± 1.52
0.54
 1
 0.31
 0.65 ± 0.05
3.6 ± 0.24


C3
 1.1 ± 0.21
 0.6
 15.2
 14.6
 29.8 ± 1.55
 12.2c
 0.81
 1.44
 0.28
 0.95 ± 0.08
 0.30a
 4.98 ± 0.28
 1.38b

200
 T4
 1.88 ± 0.35
6.6
 6.6
 13.2 ± 2.07
0.36
 0.62
 0.40
 0.43 ± 0.04
3.1 ± 0.24


C4
 0.98 ± 0.22
 0.9
 16.4
 14.2
 30.6 ± 1.56
 17.4c
 0.86
 1.69
 0.28
 1.05 ± 0.07
 0.62c
 5.12 ± 0.28
 2.02c
48
 30
 t3
 2 ± 0.16
7.8
 9
 16.8 ± 0.77
0.54
 0.76
 0.45
 0.61 ± 0.08
4.56 ± 0.39


C3
 0.98 ± 0.14
 1.02b
 11
 12.8
 23.8 ± 1.34
 7.0b
 1.34
 1.28
 0.54
 1.32 ± 0.08
 0.71c
 5.9 ± 0.41
 1.34a

200
 T4
 2.34 ± 0.16
7
 7.4
 14.4 ± 0.90
0.32
 0.41
 0.50
 0.35 ± 0.02
4.06 ± 0.39


C4
 1.06 ± 0.13
 1.28c
 12
 13.8
 25.8 ± 0.96
 11.4c
 1.15
 1.41
 0.50
 1.22 ± 0.04
 0.87c
 6.02 ± 0.38
 1.96b
72
 30
 t3
 2.76 ± 0.21
5.6
 7.2
 12.8 ± 1.38
0.47
 0.64
 0.33
 0.51 ± 0.06
7.64 ± 0.16


C3
 1.7 ± 0.18
 1.06b
 9.6
 10.4
 20 ± 1.45
 7.2b
 1.65
 1.06
 0.58
 1.44 ± 0.09
 0.93c
 7.74 ± 0.30
 0.10

200
 T4
 2.9 ± 0.22
6.6
 4.4
 11 ± 1.50
0.26
 0.59
 0.30
 0.33 ± 0.05
4.86 ± 0.33


C4
 1.56 ± 0.07
 1.34c
 9.4
 11.2
 20.6 ± 1.64
 9.6c
 1.17
 1.62
 0.60
 1.32 ± 0.08
 0.99c
 7.28 ± 0.20
 2.42c
96
 30
 t3
 2.3 ± 0.23
4.6
 7.6
 12.2 ± 1.14
0.28
 0.92
 0.17
 0.37 ± 0.06
2.72 ± 0.18


C3
 1.26 ± 0.15
 1.04c
 8.2
 10.2
 18.4 ± 1.60
 6.2a
 0.86
 0.94
 0.49
 0.91 ± 0.09
 0.54c
 4.64 ± 0.34
 1.92b

200
 T4
 2.56 ± 0.26
3.2
 5.6
 9.8 ± 1.24
0.18
 0.71
 0.16
 0.25 ± 0.02
2.38 ± 0.24


C4
 1.42 ± 0.10
 1.14b
 7.4
 10.4
 17.6 ± 1.60
 7.8b
 0.94
 1.01
 0.49
 0.97 ± 0.09
 0.72c
 5.14 ± 0.19
 2.76c

a = p < 0.05, b = p < 0.01, c = p < 0.001 (significance levels of t-test) Mitotic Indices (MI) in 5000 cells (1000 cells from each individuals), Micronuclei in normochromatic erythrocytes (NCE) and polychromatic erythrocytes (PCE) in 5000 cells (1000 cells from each individuals) and Sperm head-shape abnormality (SHA) in 5000 sperm (1000 sperm from each individuals) at different fixation intervals in CdCl2 treated mice post-fed with Cad Sulph-30 (T3) and Cad Sulph-200 (T4) separately and respective alcohol-30 (C3) and alcohol-200 (C4) fed controls.

Datta et al. BMC Complementary and Alternative Medicine 2001 1:9   doi:10.1186/1472-6882-1-9